You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: chemotherapy and hormonal therapy reduce recurrence and mortality at 15 years in early breast cancer

https://doi.org/10.1136/ebm.10.6.169

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–717.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q What are the effects of adjuvant chemotherapy, tamoxifen, and ovarian ablation or suppression on recurrence and survival 15 years after diagnosis of early breast cancer?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Oncology ★★★★★★☆

    METHODS

    Embedded ImageData sources:

    Medline, published lists of randomised trials, hand searching selected journals, meeting abstracts, references of published trials and reviews, and contacting experts repeatedly over a 15 year period.

    Embedded ImageStudy selection and assessment:

    unconfounded randomised controlled trials (RCTs) of adjuvant systemic therapies for early breast cancer begun before 1995. Individual patient data and updated follow up were sought on every woman included in the studies. Analyses were by intention to treat.

    Embedded ImageOutcomes:

    main outcomes were death from breast cancer, death from other causes, breast cancer recurrence, and incidence of second cases of cancers. …

    View Full Text

    Footnotes

    • For correspondence: EBCTCG Secretariat, CTSU, Radcliffe Infirmary, Oxford, UK. bc.overview{at}ctsu.ox.ac.uk

    • Source of funding: UK Medical Research Council.